Article ID Journal Published Year Pages File Type
5528621 Molecular Oncology 2016 12 Pages PDF
Abstract
Many prognostic signatures for NB are confounded by MYCN amplification and fail to predict outcome for the subset of high-risk patients with MYCN amplification. We report a MYCN module signature that is associated with distinct patient outcomes, and predicts candidate therapeutic targets in DNA repair pathways, including PARP1 in MYCN-amplified NB.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma
Authors
, , , ,